ALNYLAM PHARMACEUTICALS, INC. Derivative Liability, Noncurrent
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had Derivative Liability, Noncurrent of $0 as of 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DerivativeLiabilitiesNoncurrent · last filed 2026-02-12
- 2025-12-31: Derivative Liability, Noncurrent $0.00.
- 2025-09-30: Derivative Liability, Noncurrent $439.66M.
- 2025-06-30: Derivative Liability, Noncurrent $407.54M.
- 2025-03-31: Derivative Liability, Noncurrent $422.43M.
| Period end | Derivative Liability, Noncurrent |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-12 |
| 2025-09-30 | $439.66M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $407.54M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $422.43M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $393.14M 10-K · filed 2026-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |